by Gabrielle Morrow | Apr 30, 2015 | Press Release
NEW YORK, N.Y. – April 30, 2015 – CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class modulator of the brain’s innate immune system, as a potential treatment for Alzheimer’s disease (AD), announced today it has appointed Sophie Egholm...
by Gabrielle Morrow | Nov 5, 2014 | In the News
NOVEMBER 5, 2014 – BioPharm Insight -London,U.K. and New York, N.Y – CereSpir is in active discussions with multiple pharma companies to secure a partnership or financing to run two Phase III trials of its Alzheimer’s disease (AD) drug candidate...